explore -WSS

explore

author：leisure time 2025-10-02 00:29:18 - browse：76

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： STAT Readout Newsletter: Today's biggest biotech updates

WSS

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

STAT Readout Newsletter: Today's biggest biotech updates

UnitedHealth’s board chair also owns a personal investment firm

What is the Turing Test that determines if computers can think?

STAT Summit: GSK CEO on pharma giant's new direction

Listen: BridgeBio's big week & Lilly's Alzheimer's data

focus

explore

focus

23andMe had bad news about my health. I wish a person had delivered it

NIH confirmation hearing shows politicization of research

How one medical school became remarkably diverse

How Brent Saunders' Allergan experiment failed

Medical leaders decry Supreme Court decision on affirmative action

FDA gives detailed accounting of AI

United colonoscopy coverage change 'may cost lives,' doctors say

A new deal aims to ramp up use of AI in rehab care decisions

Medical records are filled with copy

STAT Readout Newsletter: Today's biggest biotech updates

knowledge

EMA weighs against approval for Mirati's lung cancer drug

FDA warns J&J's Abiomed: We will regulate your software

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

EMA weighs against approval for Mirati's lung cancer drug

Hey, doctors: Don't be no

Hey, doctors: Don't be no

hotspot

hotspot

knowledge

entertainment